Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in adults with type 2 diabetes without established heart disease
ACTRN12619000887178Phase 4Recruiting
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Baker Heart and Diabetes Institute. Primary endpoints: Change in peak oxygen consumption and Change in muscle sympathetic nerve activity. Started Jul 2019; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12619000887178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000887178.